CB-839

DRUG9 trials

Sponsors

Calithera Biosciences, Inc, David Bajor, MD

Conditions

Acute Lymphocytic Leukemia (ALL)Acute Myeloid Leukemia (AML)Advanced Renal Cell CarcinomaCRCClear Cell Renal Cell CarcinomaClear Cell Renal Cell Carcinoma (ccRCC)Colon CancerColorectal Cancer

Phase 1

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

CompletedNCT02071862

Calithera Biosciences, IncFumarate Hydratase (FH)-Deficient Tumors, Mesothelioma, Non Small Cell Lung Cancer +7

Start: 2014-02-28End: 2019-03-31Updated: 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

CompletedNCT02071888

Calithera Biosciences, IncMultiple Myeloma, Non-Hodgkin's Lymphoma (NHL), Other B-cell NHL Subtypes, Including WM +2

Start: 2014-02-28End: 2016-04-30Updated: 2018-07-18

Study of the Glutaminase Inhibitor CB-839 in Leukemia

CompletedNCT02071927

Calithera Biosciences, IncAcute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML)

Start: 2014-03-31End: 2016-12-31Updated: 2017-02-09

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

TerminatedNCT02771626

Calithera Biosciences, IncClear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)

Start: 2016-08-01End: 2020-04-24Updated: 2023-03-17

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

CompletedNCT02861300

David Bajor, MDColon Cancer, Colorectal Cancer, Rectal Cancer +1

Start: 2016-09-12End: 2023-01-10Updated: 2024-12-19

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

TerminatedNCT03875313

Calithera Biosciences, IncccRCC, Clear Cell Renal Cell Carcinoma, Colorectal Cancer +4

Start: 2019-05-20End: 2020-07-29Updated: 2022-02-17

Phase 2

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

CompletedNCT03057600

Calithera Biosciences, IncTNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer

Start: 2017-05-01End: 2019-11-25Updated: 2022-09-28

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

CompletedNCT03163667

Calithera Biosciences, IncClear Cell Renal Cell Carcinoma

Start: 2017-09-06End: 2020-06-01Updated: 2022-09-15

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

CompletedNCT03428217

Calithera Biosciences, IncAdvanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma

Start: 2018-04-24End: 2021-07-16Updated: 2023-03-20

Related Papers

Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment.

2024-10-2728 citations

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma

JAMA Oncology2022-09-01129 citations

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Clinical Cancer Research2022-05-1697 citations

CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.

Journal of Clinical Oncology2021-05-2041 citations

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma.

2020-05-2012 citations

CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.

Journal of Clinical Oncology2019-03-0152 citations

CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.

Journal of Clinical Oncology2019-03-019 citations

Abstract P6-20-07: Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study

Cancer Research2019-02-1515 citations

CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.

Journal of Clinical Oncology2018-05-2018 citations

Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors.

Journal of Clinical Oncology2018-05-2016 citations

Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).

Journal of Clinical Oncology2018-02-2025 citations

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Blood2016-12-0213 citations

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).

Journal of Clinical Oncology2016-05-2042 citations

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).

Journal of Clinical Oncology2016-05-2025 citations

Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.

Journal of Clinical Oncology2015-05-2059 citations